Global Cervical Cancer Diagnostics and Therapeutics Market Size

Cervical Cancer Diagnostics and Therapeutics Market Analysis

The Global Cervical Cancer Diagnostics and Therapeutics Market size is expected to grow from USD 95.69 billion in 2023 to USD 124.74 billion by 2028, at a CAGR of 5.44% during the forecast period (2023-2028).

The COVID-19 pandemic had a serious impact on cervical cancer diagnosis and treatment. According to the study published in the Diagnostics Journal in April 2022, during the first lockdown in April 2020, the number of tests dropped by 75.5%, after which the number of cases dropped by up to 36.1% in 2021. During the first 24 months of the pandemic, the total volume of tests lost was 49.9%. The percentage of late-stage cervical cancers (stages III-IV) increased by 17%, while the number of newly diagnosed cancers in the outpatient clinic decreased by 45% from the baseline. However, the market growth is stabilizing in the current scenario after COVID-19 as the worldwide restrictions have eased and disease screening services have been resumed.

The factors propelling the growth of the cervical cancer diagnostics and therapeutics market are favorable government initiatives towards cervical cancer prevention, the growing prevalence of cervical cancer, increasing awareness regarding early diagnosis, and strong R&D from key players in cervical cancer diagnosis and drugs. For instance, in May 2022, the National Health Mission (NHM) and the Clinton Health Access Initiative launched a training program for gynecologists and nurses in Uttar Pradesh (India) with the goal of detecting cervical cancer cases at an early stage. These kinds of government programs help find and treat cervical cancer early, which is good for market growth.

The market studied has been witnessing considerable growth, which is attributed to the increasing prevalence of cervical cancer among women worldwide. WHO Updates in February 2022 say that cervical cancer is the fourth most common cancer in women around the world, with 604,000 new cases and 342,000 deaths by 2020.In 2020, low- and middle-income countries will account for nearly 90% of new cases and deaths worldwide. As more people use cervical cancer diagnostic tests to find early signs of the disease, the market is likely to grow.

Additionally, the launch of more efficient combination drugs and tests is expected to boost the growth of the cervical cancer diagnostics and therapeutics market. For instance, in September 2021, the US FDA granted accelerated approval to tisotumab vedotin-tftv, a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer with disease progression during or after chemotherapy. In the same way, in October 2021, the US FDA approved pembrolizumab in combination with chemotherapy, with or without bevacizumab, for people with persistent, recurring, or metastatic cervical cancer whose tumors express PD-L1 (CPS 1), as shown by an FDA-approved test.

But in many countries, testing isn't done regularly because of money problems, and the high cost of cancer treatments slows market growth.